MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer

Immunotherapy. 2015;7(11):1133-4. doi: 10.2217/imt.15.84. Epub 2015 Nov 16.

Authors

Pedro Nazareth Aguiar Jr¹, Hakaru Tadokoro¹, Nora Manoukian Forones², Ramon Andrade de Mello^{3

4}

Affiliations

¹ Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
² Gastrointestinal Oncology Service, Gastroenterology Department, Federal University of São Paulo, São Paulo, Brazil.
³ Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal.
⁴ Faculty of Medicine, University of Porto, Porto, Portugal.

PMID: 26568256
DOI: 10.2217/imt.15.84

No abstract available

Keywords: MMR; colorectal cancer; immunotherapy; pembrolizumab.

Publication types

Editorial
Review

MeSH terms

Animals
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, Neoplasm / genetics
Antigens, Neoplasm / metabolism*
Antineoplastic Agents / therapeutic use
Brain Neoplasms / complications
Brain Neoplasms / immunology
Brain Neoplasms / therapy*
Clinical Trials as Topic
Colorectal Neoplasms / complications
Colorectal Neoplasms / immunology
Colorectal Neoplasms / therapy*
Humans
Mutation / genetics
Neoplasm Metastasis
Neoplastic Syndromes, Hereditary / complications
Neoplastic Syndromes, Hereditary / immunology
Neoplastic Syndromes, Hereditary / therapy*
Programmed Cell Death 1 Receptor / immunology*
Tumor Escape / drug effects

Substances

Antibodies, Monoclonal, Humanized
Antigens, Neoplasm
Antineoplastic Agents
Programmed Cell Death 1 Receptor
pembrolizumab

Supplementary concepts

Turcot syndrome